MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Rating Upgraded by Wall Street Zen

MIRA Pharmaceuticals (NASDAQ:MIRA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a report on Saturday, September 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

MIRA Pharmaceuticals Stock Performance

MIRA opened at $1.35 on Friday. The firm has a market cap of $25.74 million, a P/E ratio of -2.76 and a beta of 1.69. The firm has a 50-day moving average of $1.42 and a 200 day moving average of $1.29. MIRA Pharmaceuticals has a fifty-two week low of $0.73 and a fifty-two week high of $2.56.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. Equities research analysts predict that MIRA Pharmaceuticals will post -0.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of MIRA Pharmaceuticals in the second quarter worth approximately $26,000. Creative Planning bought a new position in shares of MIRA Pharmaceuticals in the second quarter worth approximately $27,000. International Assets Investment Management LLC bought a new position in shares of MIRA Pharmaceuticals in the second quarter worth approximately $42,000. Suncoast Equity Management grew its holdings in shares of MIRA Pharmaceuticals by 356.1% in the first quarter. Suncoast Equity Management now owns 103,289 shares of the company’s stock worth $101,000 after purchasing an additional 80,645 shares during the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of MIRA Pharmaceuticals in the fourth quarter worth approximately $28,000. 35.16% of the stock is currently owned by institutional investors.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.